0000000000643028

AUTHOR

Valentina B. Zubek

showing 3 related works from this author

Tiotropium Respimat® Add-On To Inhaled Corticosteroids Improves Lung Function In Patients With Symptomatic Mild Asthma: Results From A Phase III Trial

2014

medicine.medical_specialtyRespimatbusiness.industryAnesthesiaImmunologyMild asthmaPhysical therapymedicineImmunology and AllergyInhaled corticosteroidsIn patientbusinessLung functionJournal of Allergy and Clinical Immunology
researchProduct

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

2014

BackgroundTiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated efficacy in patients with asthma who were symptomatic despite treatment with medium- to high-dose inhaled corticosteroids (ICS).ObjectiveThe objective of this study was to evaluate the efficacy and safety of once-daily tiotropium Respimat (5 μg or 2.5 μg), compared with placebo Respimat, as add-on therapy to low- to medium-dose ICS for adults with symptomatic asthma.MethodsA phase III, double-blind, placebo-controlled trial was conducted (NCT01316380). Adults with symptomatic asthma receiving low- to medium-dose ICS (200-400 μg budesonide or equivalent dose) and a pre-bronchodilator forced expira…

SpirometryBudesonideAdultMaleRespimatmedicine.drug_classSymptomaticAnticholinergicMildPlacebo03 medical and health sciences0302 clinical medicineBronchodilatorsAdrenal Cortex HormonesBronchodilatorControlAdministration InhalationImmunology and AllergyMedicineHumans030212 general & internal medicineTiotropium BromideBudesonideAnticholinergic; Asthma; Bronchodilators; Control; GINA; ICS; Mild; Respimat; Symptomatic; Tiotropium; Administration Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchodilator Agents; Budesonide; Disease Progression; Drug Combinations; Female; Humans; Male; Placebo Effect; Spirometry; Tiotropium Bromide; Treatment Outcome; Immunology and AllergyAsthmamedicine.diagnostic_testbusiness.industryTiotropiumTiotropium bromidemedicine.diseasePlacebo EffectGINAAsthmarespiratory tract diseasesRespimatBronchodilator AgentsDrug CombinationsTreatment OutcomeInhalation030228 respiratory systemTolerabilityICSSpirometryAnesthesiaAdministrationDisease ProgressionFemalebusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

P260 Tiotropium Respimat(R) Add-on To Inhaled Corticosteroids Improves Lung Function In Patients With Symptomatic Mild Asthma: Results From A Phase I…

2014

Background Despite currently available therapies and detailed guidelines, many people with mild asthma remain symptomatic; it is important to establish the efficacy and safety of new treatments in this group. Methods A Phase III, randomised, double-blind, parallel-group trial (GraziaTinA-asthma ® ; NCT01316380) evaluated the efficacy and safety of once-daily tiotropium 5 µg or 2.5 µg versus placebo (all delivered via the Respimat ® SoftMist™ inhaler) for 12 weeks in patients with symptomatic asthma on low-dose inhaled corticosteroids (200–400 µg budesonide or equivalent). The primary end point was peak forced expiratory volume in 1 second (FEV 1 ) within 3 h of dosing (0–3h) response (chang…

Pulmonary and Respiratory MedicineBudesonideRespimatbusiness.industryInhalerArea under the curvePlacebomedicine.diseaserespiratory tract diseasesAnesthesiamedicineDosingAdverse effectbusinessmedicine.drugAsthmaThorax
researchProduct